THE MISSING
PIECE IN LIPID
MANAGEMENT
1
Lipanthyl + Sta
tin
Better Outcome
Reference: 1.
*UXQG\ 60 9HJD */ <XDQ = %DWWLVWL :3 %UDG\ :( 3DOPLVDQR - (IIHFWLYHQHVV DQG 7ROHUDELOLW\ RI 6LPYDVWDWLQ 3OXV )HQR¿EUDWHIRU &RPELQHG
Hyperlipidemia (The SAFARI Trial).
$P - &DUGLRO
2005;
95
:462-468.
S3 LIPANTHYL
®
PJ (DFK FDSVXOH FRQWDLQV PJ IHQR¿EUDWH PLFURQLVHG 5HJ 1R
For full prescribing information refer to the package insert approved by the Medicines RegulatoryAuthority. Date of Publication of this Promotional Material: May 2014.Abbott Laboratoriets
6 $ 3W\ /LPLWHG $EERWW 3ODFH *ROI &OXE 7HUUDFH &RQVWDQWLD .ORRI
7HO 1R
3URPR 1R =$(/,/
ONE TABLET
ONCE DAILY
WITH FOOD
• Fenofibrate plus simvastatin therapy significantly improved ALL lipoprotein
abnormalities vs simvastatin alone (p < 0,001)
1
Combination fenofibrate plus simvastatin
therapy in patients with mixed dyslipidaemias
7* WULJO\FHULGH 7& WRWDO FKROHVWHURO /'/ & ORZ GHQVLW\ OLSRSURWHLQ FKROHVWHURO
+'/ & KLJK GHQVLW\ OLSRSURWHLQ FKROHVWHURO $SR % DSROLSRSURWHLQ %
Adapted from Grundy SM, et al
1
Change from baseline in lipid parameters
1
Simvastatin
Fenofibrate + Simvastatin
30
20
10
0
-10
-20
-30
-40
-50
Percentage change from baseline (%)
-43,0
-20,0
-26,3
-31,2
-35,3
-32,6
18,6
-26,1
-22,8
-20,3
-25,8
TG
TC
LDL-C
HDL-C non-HDL-C
Apo B
9,7
p < 0,001
